607 related articles for article (PubMed ID: 30071384)
1. Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder.
Lim Z; Wong K; Downs J; Bebbington K; Demarest S; Leonard H
Epilepsy Res; 2018 Oct; 146():36-40. PubMed ID: 30071384
[TBL] [Abstract][Full Text] [Related]
2. Use of the ketogenic diet to manage refractory epilepsy in CDKL5 disorder: Experience of >100 patients.
Lim Z; Wong K; Olson HE; Bergin AM; Downs J; Leonard H
Epilepsia; 2017 Aug; 58(8):1415-1422. PubMed ID: 28605011
[TBL] [Abstract][Full Text] [Related]
3. Clinical manifestations and epilepsy treatment in Japanese patients with pathogenic CDKL5 variants.
Kobayashi Y; Tohyama J; Takahashi Y; Goto T; Haginoya K; Inoue T; Kubota M; Fujita H; Honda R; Ito M; Kishimoto K; Nakamura K; Sakai Y; Takanashi JI; Tanaka M; Tanda K; Tominaga K; Yoshioka S; Kato M; Nakashima M; Saitsu H; Matsumoto N
Brain Dev; 2021 Apr; 43(4):505-514. PubMed ID: 33436160
[TBL] [Abstract][Full Text] [Related]
4. Amelioration of intractable epilepsy by adjunct vagus nerve stimulation therapy in a girl with a CDKL5 mutation.
Baba S; Sugawara Y; Moriyama K; Inaji M; Maehara T; Yamamoto T; Morio T
Brain Dev; 2017 Apr; 39(4):341-344. PubMed ID: 27823948
[TBL] [Abstract][Full Text] [Related]
5. Vagus nerve stimulation for super-refractory status epilepticus in febrile infection-related epilepsy syndrome: a pediatric case report and literature review.
Luo T; Wang Y; Lu G; Zhou Y; Wang Y
Childs Nerv Syst; 2022 Jul; 38(7):1401-1404. PubMed ID: 34762158
[TBL] [Abstract][Full Text] [Related]
6. Quality-of-life metrics with vagus nerve stimulation for epilepsy from provider survey data.
Englot DJ; Hassnain KH; Rolston JD; Harward SC; Sinha SR; Haglund MM
Epilepsy Behav; 2017 Jan; 66():4-9. PubMed ID: 27974275
[TBL] [Abstract][Full Text] [Related]
7. Insufficient efficacy of vagus nerve stimulation for epileptic spasms and tonic spasms in children with refractory epilepsy.
Okanishi T; Fujimoto A; Nishimura M; Kanai S; Motoi H; Homma Y; Enoki H
Epilepsy Res; 2018 Feb; 140():66-71. PubMed ID: 29287185
[TBL] [Abstract][Full Text] [Related]
8. Learnings from 30 years of reported efficacy and safety of vagus nerve stimulation (VNS) for epilepsy treatment: A critical review.
Toffa DH; Touma L; El Meskine T; Bouthillier A; Nguyen DK
Seizure; 2020 Dec; 83():104-123. PubMed ID: 33120323
[TBL] [Abstract][Full Text] [Related]
9. Vagus nerve stimulation for refractory epilepsy: experience from Saudi Arabia.
Al-Said Y; Baeesa S; Khalid M; Abdeen M; Kayyali HR
Ann Saudi Med; 2015; 35(1):41-5. PubMed ID: 26142937
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety following two or more years of vagus nerve stimulation (VNS Therapy) in pediatric patients with drug-resistant epilepsy enrolled in a Russian VNS Registry.
Feygina AA; Koshelyaevskaya YN; Dibué M; Voronkova KV; Klochkov MN; Koroleva NY; Ivanov SS; Bolshakova ES; Fatykhova EF
Brain Behav; 2023 Jul; 13(7):e3076. PubMed ID: 37254623
[TBL] [Abstract][Full Text] [Related]
11. Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder.
Olson HE; Daniels CI; Haviland I; Swanson LC; Greene CA; Denny AMM; Demarest ST; Pestana-Knight E; Zhang X; Moosa AN; Fidell A; Weisenberg JL; Suter B; Fu C; Neul JL; Percy AK; Marsh ED; Benke TA; Poduri A
J Neurodev Disord; 2021 Sep; 13(1):40. PubMed ID: 34530725
[TBL] [Abstract][Full Text] [Related]
12. Vagus nerve stimulation for patients with refractory epilepsy: Demographic features and neuropsychological outcomes of the VNS Taiwan child neurology society database.
Tsai JD; Yang RC; Chang MY; Fan HC; Hung KL; Tcns VNS
Epilepsy Behav; 2020 Oct; 111():107186. PubMed ID: 32534423
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effects of children with refractory epilepsy after vagus nerve stimulation in Taiwan.
Li ST; Chiu NC; Hung KL; Ho CS; Kuo YT; Wu WH;
Pediatr Neonatol; 2020 Dec; 61(6):606-612. PubMed ID: 32773364
[TBL] [Abstract][Full Text] [Related]
14. An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug resistant epilepsy in the United States.
Raspin C; Faught E; Armand J; Barion F; Pollit V; Murphy J; Danielson V
J Med Econ; 2023; 26(1):189-199. PubMed ID: 36691763
[TBL] [Abstract][Full Text] [Related]
15. Clinical features of early myoclonic encephalopathy caused by a CDKL5 mutation.
Takeda K; Miyamoto Y; Yamamoto H; Ishii A; Hirose S; Yamamoto H
Brain Dev; 2020 Jan; 42(1):73-76. PubMed ID: 31492455
[TBL] [Abstract][Full Text] [Related]
16. CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.
Demarest ST; Olson HE; Moss A; Pestana-Knight E; Zhang X; Parikh S; Swanson LC; Riley KD; Bazin GA; Angione K; Niestroj LM; Lal D; Juarez-Colunga E; Benke TA
Epilepsia; 2019 Aug; 60(8):1733-1742. PubMed ID: 31313283
[TBL] [Abstract][Full Text] [Related]
17. Estimating Long-Term Vagus Nerve Stimulation Effectiveness: Accounting for Antiepileptic Drug Treatment Changes.
Révész D; Fröjd V; Rydenhag B; Ben-Menachem E
Neuromodulation; 2018 Dec; 21(8):797-804. PubMed ID: 29608227
[TBL] [Abstract][Full Text] [Related]
18. Long-term seizure and psychosocial outcomes of vagus nerve stimulation for intractable epilepsy.
Wasade VS; Schultz L; Mohanarangan K; Gaddam A; Schwalb JM; Spanaki-Varelas M
Epilepsy Behav; 2015 Dec; 53():31-6. PubMed ID: 26515157
[TBL] [Abstract][Full Text] [Related]
19. Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder.
Devinsky O; King L; Schwartz D; Conway E; Price D
Epilepsia; 2021 Jul; 62(7):e98-e102. PubMed ID: 33979451
[TBL] [Abstract][Full Text] [Related]
20. Outcome of vagus nerve stimulation for drug-resistant epilepsy: the first three years of a prospective Japanese registry.
Kawai K; Tanaka T; Baba H; Bunker M; Ikeda A; Inoue Y; Kameyama S; Kaneko S; Kato A; Nozawa T; Maruoka E; Osawa M; Otsuki T; Tsuji S; Watanabe E; Yamamoto T
Epileptic Disord; 2017 Sep; 19(3):327-338. PubMed ID: 28832004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
